NasdaqCM - Delayed Quote USD

bioAffinity Technologies, Inc. (BIAF)

2.5400 -0.1300 (-4.87%)
At close: May 28 at 4:00 PM EDT
2.4814 -0.06 (-2.31%)
After hours: May 28 at 6:34 PM EDT
Loading Chart for BIAF
DELL
  • Previous Close 2.6700
  • Open 2.6400
  • Bid 2.4800 x 100
  • Ask 2.5500 x 400
  • Day's Range 2.4904 - 2.6599
  • 52 Week Range 0.9550 - 3.6200
  • Volume 74,996
  • Avg. Volume 263,567
  • Market Cap (intraday) 28.49M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9300
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.

www.bioaffinitytech.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIAF

Performance Overview: BIAF

Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BIAF
72.67%
S&P 500
11.24%

1-Year Return

BIAF
35.11%
S&P 500
26.17%

3-Year Return

BIAF
69.76%
S&P 500
33.76%

5-Year Return

BIAF
69.76%
S&P 500
33.76%

Compare To: BIAF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIAF

Valuation Measures

Annual
As of 5/28/2024
  • Market Cap

    28.63M

  • Enterprise Value

    27.67M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.93

  • Price/Book (mrq)

    5.70

  • Enterprise Value/Revenue

    5.87

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -48.85%

  • Return on Equity (ttm)

    -99.85%

  • Revenue (ttm)

    2.53M

  • Net Income Avi to Common (ttm)

    -7.94M

  • Diluted EPS (ttm)

    -0.9300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.82M

  • Total Debt/Equity (mrq)

    32.51%

  • Levered Free Cash Flow (ttm)

    -3.61M

Research Analysis: BIAF

Company Insights: BIAF

Research Reports: BIAF

People Also Watch